Literature DB >> 16244506

New guidelines on anaemia management in patients with cancer: How do these affect clinical practice?

Gunnar Birgegård1, Carsten Bokemeyer.   

Abstract

Anaemia is a condition that frequently occurs in patients with cancer, but a recent survey has cast doubt over whether it is being appropriately treated. These findings are disappointing considering the wealth of data showing the effectiveness of epoetin therapy in patients with cancer. Recently, evidence-based guidelines have been published that aim to provide physicians with the latest information required for optimal management of anaemia in patients with cancer. By increasing physician awareness of the appropriate therapy for anaemia management, more patients may receive the benefits of epoetin therapy. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244506     DOI: 10.1159/000088284

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Restrictive blood transfusion protocol in malignant upper gastrointestinal and pancreatic resections patients reduces blood transfusions with no increase in patient morbidity.

Authors:  John Wehry; Steven Agle; Prejesh Philips; Robert Cannon; Charles R Scoggins; Lisa Puffer; Kelly M McMasters; Robert C G Martin
Journal:  Am J Surg       Date:  2015-09-30       Impact factor: 2.565

2.  Restrictive blood transfusion protocol in liver resection patients reduces blood transfusions with no increase in patient morbidity.

Authors:  John Wehry; Robert Cannon; Charles R Scoggins; Lisa Puffer; Kelly M McMasters; Robert C G Martin
Journal:  Am J Surg       Date:  2014-08-06       Impact factor: 2.565

3.  Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer.

Authors:  Myong Cheol Lim; Joo-Young Kim; Tae-Hyun Kim; Sohee Park; Sun-Young Kong; Jung-Hyun Yoon; Sokbom Kang; Sang-Soo Seo; Sang Yoon Park
Journal:  Yonsei Med J       Date:  2008-12-31       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.